Created with the purchase of a small Sanofi pharmaceutical manufacturing plant in Amiens (France), Unither grew rapidly through sterile unit dose manufacture using Blow-Fill-Seal technology (BFS), and a unique pricing structure.
Implemented the strategy of a specialized focus on sterile unit dose manufacturing.
Unither goes International
Expanded international markets with exports to Europe and development of commercial, operational and regulatory capacity for international customers.
Unither joined forces with a financial partner to accelerate the group's development, particularly through external growth.
Growth & Expansion
Unither acquired a second manufacturing site in Coutances (France) for its sterile unit dose manufacture.
Product & Service Diversification
Diversified with effervescent products, non-sterile liquid forms, and pharmaceutical development with the acquisition of Créapharm in 2005.
Additional Specialized Manufacturing
The launch of Unistick® stick-pack for liquid and paste forms marked a major advance for our ability to offer unique unit dose solutions.
Unither purchased the Colomiers (France) site from Sanofi-Aventis, gaining a competitive platform for the production of high volumes of Unistick®.
Another Cutting-Edge Product
Introduced Uniflash®, a new, patented, BTM (Buccal Trans-Mucous) drug delivery system that is comparable to an intravenous solution.
In response to customer needs, we opened commercial offices in Brazil, a growing pharmaceutical market with a huge potential for drug products.
Entering the US
With the acquisition of a manufacturing plant in Rochester (USA) from UCB, Unither expanded once again. This was a major turning point; directly entering the North American market with tablets, hard capsules, liquid forms, BFS and liquid-stick-pack.
Acquisition of Barretos Plant
With the acquisition of a manufacturing plant in Barretos we strengthened our presence in Brazil.
A new Cutting-Edge Product: ODX
The orodispersible dosage forms have been developed to improve swallowing of oral dosage forms particularly for patients with dysphagia such as geriatric and pediatric population.
Opening of a Chinese subsidiary in Wuhan in order to bring innovative technologies to Chinese pharmaceutical laboratories and patients